Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Treasury Shares: 2020-2025

Historic Treasury Shares for Xeris Biopharma Holdings (XERS) over the last 1 years, with Sep 2025 value amounting to $13.8 million.

  • Xeris Biopharma Holdings' Treasury Shares was N/A to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year change of. This contributed to the annual value of $16.4 million for FY2024, which is 41.81% up from last year.
  • Xeris Biopharma Holdings' Treasury Shares amounted to $13.8 million in Q3 2025, which was down 4.78% from $14.5 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Treasury Shares high stood at $16.4 million for Q4 2024, and its period low was $2.1 million during Q3 2021.
  • In the last 3 years, Xeris Biopharma Holdings' Treasury Shares had a median value of $14.5 million in 2025 and averaged $14.3 million.
  • Data for Xeris Biopharma Holdings' Treasury Shares shows a peak YoY skyrocketed of 120.33% (in 2023) over the last 5 years.
  • Xeris Biopharma Holdings' Treasury Shares (Quarterly) stood at $2.1 million in 2021, then reached $5.3 million in 2022, then spiked by 120.33% to $11.6 million in 2023, then soared by 41.81% to $16.4 million in 2024, then reached $13.8 million in 2025.
  • Its Treasury Shares was $13.8 million in Q3 2025, compared to $14.5 million in Q2 2025 and $15.1 million in Q1 2025.